1. Home
  2. FBRT vs TBPH Comparison

FBRT vs TBPH Comparison

Compare FBRT & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Franklin BSP Realty Trust Inc.

FBRT

Franklin BSP Realty Trust Inc.

HOLD

Current Price

$9.28

Market Cap

882.8M

Sector

Real Estate

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$18.16

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FBRT
TBPH
Founded
2012
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
882.8M
1.0B
IPO Year
N/A
2013

Fundamental Metrics

Financial Performance
Metric
FBRT
TBPH
Price
$9.28
$18.16
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
5
Target Price
$14.00
$27.80
AVG Volume (30 Days)
1.2M
386.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
8.86%
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.88
Revenue
N/A
$15,386,000.00
Revenue This Year
$25.99
$70.90
Revenue Next Year
N/A
N/A
P/E Ratio
$13.56
$21.66
Revenue Growth
N/A
N/A
52 Week Low
$8.42
$7.90
52 Week High
$13.58
$21.03

Technical Indicators

Market Signals
Indicator
FBRT
TBPH
Relative Strength Index (RSI) 44.42 38.56
Support Level $8.42 $13.58
Resistance Level $10.98 $19.04
Average True Range (ATR) 0.26 0.95
MACD -0.03 -0.14
Stochastic Oscillator 44.96 9.89

Price Performance

Historical Comparison
FBRT
TBPH

About FBRT Franklin BSP Realty Trust Inc.

Franklin BSP Realty Trust Inc is a private real estate investment trust that originates, acquires, and manages a diversified portfolio of commercial real estate debt, and first mortgage loans. secured by properties located in the United States. Its segments include the real estate debt business; the real estate securities business; the real estate owned business; and the commercial real estate conduit business.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: